Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985507 | 1.00 | PRKCI (0.39) | PRKCINAPRTTP53MAPTHTT | |
| SCHEMBL982682 | 0.87 | PABPC1 (0.40) | PRKCINAPRTMAPTHTTSHMT2 | |
| SCHEMBL11946796 | 0.87 | PABPC1 (0.40) | PRKCINAPRTMAPTHTTSHMT2 | |
| SCHEMBL982681 | 0.87 | PABPC1 (0.40) | PRKCINAPRTMAPTHTTSHMT2 | |
| SCHEMBL14399255 | 0.86 | TP53 (0.37) | PRKCINAPRTTP53MAPTHTT | |
| SCHEMBL984245 | 0.83 | PIK3CD (0.38) | PRKCITP53L3MBTL1KDM4EPOLB | |
| SCHEMBL984244 | 0.83 | PIK3CD (0.38) | PRKCITP53L3MBTL1KDM4EPOLB | |
| SCHEMBL11946795 | 0.83 | PIK3CD (0.38) | PRKCITP53L3MBTL1KDM4EPOLB | |
| SCHEMBL985872 | 0.81 | PRKCI (0.57) | PRKCINAPRTTP53MAPTHTT | |
| SCHEMBL4831450 | 0.79 | BRAF (0.44) | TP53L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | PRKCI 4/4885NAPRT 4625/4885TP53 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.